Thursday, April 28, 2011

Raw recovery Wang yawei bottom guangji pharmaceutical industry

Each in guangji pharmaceutical announced today by reporter Zhao Di (000952, unit) (000952, $ 12.34 per cent) in a quarterly bulletin, Wang yawei its China market, Chinese policy of quietly breakdown of second or third largest shares of the Fund shareholders, holding up to 6 million of the total shares. Performance increase 80% "viagra" approaching a quarter display, guangji pharmaceutical industry achieved revenue of $ 125.5 million, up by 8.72%. However, net profit was an increase of 85.71%, amounting to $ 8.0286 million. For this, the company said, due to the smaller base of comparison with the same period a year earlier, larger net profit growth.
Recommended reading · hexun.com friends 19 stock market experience
· instant closed Fund discount ranked table Fund "88 spot curse" reproduction unit base gankao April: Qian ten name left seven to three private second quarter layout route exposure private stress defence five even fell small disk unit last a fell huge group plunged 23% 11 Fund floating losses had billion 36 unit decreases super market fund floating losses 7,800,002 quarter investment policy will hot registration in the in a quarter late wide JI drug industry Qian ten circulation unit shareholders in the, most cattle Fund Manager Wang yawei in charge of of Huaxia market selected and Huaxia policy selected respectively ranked dier、sanwei, holding number respectively about for 4 million unit and 2 million unit. And as always, Wang yawei did not go to guangji pharmaceutical research. Company also said that the investigation and has not received a body during the reporting period.
Then Wang yawei intervention guangji pharmaceutical industry eyes on what exactly is this? Cost pressures all ease the daily economic news reporter found that in recent years, subject to the rise in raw material prices, guangji pharmaceutical industry has been performance average.
Last 3 years, net profit growth rate of-,-51.53%,-51.73%, respectively, is falling. As the main products of guangji pharmaceutical industry, riboflavin gross margins have been suppressed by the high price of corn starch.
According to estimates, riboflavin guangji pharmaceutical product consumption weights about 16~20 tons of corn starch, the prices of agricultural products constitutes bad for the company. However, some analysts point out that, with the expansion of the corn planted area, influence of raw material prices on guangji pharmaceutical industry is expected to decrease. According to the universal Denon (600,371, unit) (600,371, $ 13.94 per cent) annual report revealed that the 2010 National hybrid corn planted area of more than in 2009 nearly 20 million acres, about total planted area of about 475 million acres. 2011 hybrid corn planted area was expected to further increase could reach record high of 490 million mu.
Analysts pointed out that corn acreage increased, in addition to good maize seed companies, also good guangji pharmaceutical industry. Raw material industries reported strong recovery, April 21 this year, over more than 1000 raw medicine production enterprises meet in Chengdu 66th international medical raw materials in China, came on raw material price increases of the sound. Due to the rising price of raw materials, and Jiangsu and Zhejiang provinces area environmental power rationing and other reasons, nitrate from the original $ 100/kg, up to 120 Yuan/kg. At the same time, prices of vitamins B1, B6, also rose.
This year, the Hui pharmacognostic Hubei guangji pharmaceutical subsidiary company producing 1000 tons of vitamin B6 project has to be put into production. Worth noting is that 2008 has been depressed since the raw materials industry in 2010 hit a turnaround. Statistics show that in 2010, chemical raw materials imports amounted to us $ 3.3 billion, an increase of 10%; exports totalled US $ 13.78 billion, an increase of 22.66%.
In 2010, the raw material exports exceeded $ 100 million business in China has reached 26, an increase of around 30%.
Experts say China raw material is out of the shadow of the economic crisis, global generic drug market and industry, provides an opportunity for raw materials in China to further expand the international market and the space, the most recent two years increased raw material prices is a general trend. Gold hundred provisional Advisory Qin Hong, an analyst pointed out that historical experience shows that once the price rise of chemical raw, so in the short-term trend will have two clear direction: first, product price rises fell, such as 2008-2009 VE price; second, elastic performance of listed companies is rapidly released. Perhaps, precisely because bullish on recovery of raw materials industries, Wang yawei decided to copy the guangji pharmaceutical at the end.

"manuscript statement" without the daily economic news authorized use, offenders.
if you want to reprint or learn more about the highlights, log's official website: http://www.NBD.com.CN